ClinicalTrials.gg
Not yet recruitingNCT07661446Updated Oct 9, 2026

Cannabis and Opioid Use Disorder, Study 2

A Phase 1 interventional study of Inhaled Cannabis and Intranasal Opioid in Opioid Use Disorders and Cannabis Use, sponsored by University of Kentucky. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Kentucky · Phase 1, Interventional, and Basic science

How we know

Updated Oct 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Planned enrollment
388th of 1,098
100 · median 56
Started
2026
with 83 others
Phase 1
132 of 1,223
24 open now
Primary completion
2029-07
later than 288 of 315 live
Registered
1,198th of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 388th largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 84 that started in 2026, is one of 132 in phase 1, reaches primary completion later than 288 of the 315 other live ones, and was the 1,198th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.

03

Conditions studied

  • Opioid Use Disorders
  • Cannabis Use

Keywords

  • Cannabis
  • marijuana
  • opioid
  • opioid use disorder
  • opioid withdrawal
  • opioid interaction
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with moderate to severe opioid use disorder

Exclusion criteria

Exclusion Criteria:

  • Individuals who do not use opioids or do not experience opioid withdrawal when they stop using opioids
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Oral cannabis (placebo)

    Participants will receive placebo oral cannnabis

    Drug: Inhaled Cannabis · Drug: Intranasal Opioid

  • Experimental
    Oral cannabis (active)

    Participants will receive active oral cannabis

    Drug: Inhaled Cannabis · Drug: Intranasal Opioid

Interventions

06

What researchers measure

Primary outcomes

  1. Opioid withdrawal severity

    Opioid severity is a participant-rated outcome that will be measured on a visual analog scale (0-100)

    Time frame: This outcome will be assessed regularly from baseline through 6 hours post cannabis dose during experimental sessions.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2029, 32 months later.

Of 55 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 32 months is above that.

Counting every sponsor, half of 79 studies reached it within 19 months; a quarter within 9 and three quarters within 33.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartEst.
Nov 30, 2026was Oct 2026
Primary completionEst.
Jul 30, 2029
CompletionEst.
Jan 30, 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Nov 30, 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date Oct 1, 2026→Nov 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07661446
Lead sponsor
University of Kentucky
Responsible party
Shanna Babalonis, PhD (Associate Professor, University of Kentucky) — Principal investigator
First posted
Jun 22, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Jul 30, 2029 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Paul Nuzzo
Contact
paul.nuzzo@uky.edu
859-323-0002
Shanna Babalonis, PhD
principal investigator · University of Kentucky College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa subsp. indica TOP

Start the discussion